Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of darolutamide plus ADT versus placebo plus ADT in high-risk biochemical recurrence of prostate cancer
MOH_2023-07-06_012754Phase 3Not yet recruiting
- Sponsor
- Bayer Consumer Health
- Start
- Jul 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Darolutamide + ADT with Placebo + ADT (2 arms). Planned start Jul 2023; status: not yet recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2023-07-06_012754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-07-06_012754.